GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endocyte Inc (NAS:ECYT) » Definitions » Forward PE Ratio

Endocyte (Endocyte) Forward PE Ratio : 0.00 (As of May. 06, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Endocyte Forward PE Ratio?

Endocyte's Forward PE Ratio for today is 0.00.

Endocyte's PE Ratio without NRI for today is 0.00.

Endocyte's PE Ratio for today is 0.00.


Endocyte Forward PE Ratio Historical Data

The historical data trend for Endocyte's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endocyte Forward PE Ratio Chart

Endocyte Annual Data
Trend
Forward PE Ratio

Endocyte Quarterly Data
Forward PE Ratio

Competitive Comparison of Endocyte's Forward PE Ratio

For the Biotechnology subindustry, Endocyte's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endocyte's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Endocyte's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Endocyte's Forward PE Ratio falls into.



Endocyte Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Endocyte  (NAS:ECYT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Endocyte Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Endocyte's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Endocyte (Endocyte) Business Description

Traded in Other Exchanges
N/A
Address
Endocyte Inc is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases using precision medicine. Precision medicine is a medical discipline seeking to treat diseased cells with minimal impact on healthy cells. The company uses its proprietary technology to create novel small-molecule drug conjugates and companion imaging agents. The company's therapeutic areas are non-small cell lung, breast, colorectal, kidney, endometrial, prostate, and ovarian cancers; solid tumors; polycystic kidney disease; and inflammation.
Executives
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
John C Aplin director ONE AMERICAN SQUARE STE 2850, INDIANAPOLIS IN 46282
David R. Mcavoy officer: General Counsel C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Alison A. Armour officer: Chief Medical Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Marc D Kozin director
Michael T. Andriole officer: Chief Financial Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Lesley Russell director 41 MOORES RD., FRAZER PA 19355
Beth Taylor officer: VP Finance & Chief Acctg Off 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Michael A. Sherman director, officer: President and CEO 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
Peter D Meldrum director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ann Hanham director ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Chandra D Lovejoy officer: VP of Regulatory Affairs C/O PRONAI THERAPEUTICS, INC. 2150 - 885 WEST GEORGIA ST VANCOUVER A1 V6C 3E8
David D. Meek officer: Chief Commercial Officer 3000 KENT AVENUE; SUITE A1-100, WEST LAFAYETTE IN 47906